Clinical Trial Update: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating obinutuzumab alone or with chemotherapy for chronic lymphocytic leukemia has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-29